Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say
- Novo Holdings is closing its $16.5 billion acquisition of Catalent after the FTC declines to challenge the deal.
- The deal sparked concerns about competition in the pharmaceutical industry, but regulatory conditions have been fulfilled.
- The European Commission stated that 'the proposed merger would not raise competition concerns on any of the markets examined in the EEA.'
- U.S. Consumer groups and two large labor unions urged the FTC to block the deal in October.
Insights by Ground AI
Does this summary seem wrong?
Coverage Details
Total News Sources0
Leaning Left0Leaning Right3Center5Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
C 62%
R 38%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
